The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fair points around. A necessary step. But someone once said, "nothing takes forever". With SOH/Opti I'm not so sure! And for all his failings I quite like Uncle Stephen.
Malco, if you bothered to read the Morepen related RNS you would realise this is the manufacturing agreement for the products that Dr Morepen will market and distribute financial details and timelines are ""We are pleased to announce this agreement with Morepen, a well-known and trusted supplier to pharmacies, physicians, and retail customers across India. Morepen brings an extensive sales team with experience of highly differentiated scientific products and countrywide access to a network of around 500,000 pharmacies across India. Based on current forecasts, the Directors anticipate this agreement could contribute in the region of £6-7 million revenue per annum in the next four to five years.""
Yet another deal announced but with zero financial info given and no timelines to market.
SOH is very good at producing RNS with virtually no information. Probably another deal which will not produce any meaningful revenue in the near future.
Let's see revenues from it. I've lost count of the amount of deals Opti have signed over the years, deals which generated a lot more in the way of excitement than money.
I don't like to be cynical but large paper losses and a long time invested will do that to a man.
This deal looks impressive on the surface.
Question is how much revenue from sales this will provide for Opti from royalties etc.
On the basis of 2022 FY, it will be quite a while just to break even. Based just on SlimBiome etc. Roughly 50% gross profit. And £2.75m admin costs. This ignores 20% reduction in (some?) salaries. And any accounting for stake in SBTX, PBX. And the ever elusive SweetBiotix.
SOH has talked about £7m revenue in Y5 from India deal, in RNS from Feb. And some large % increases to sales online (from low bases?). And some apparently good orders in tonnages. But I don't see FY 23 being anything other than £1m plus operating loss.
We live in hope of Sweets.
Given Optis past History and the current info we have, what is your gut feeling for Optis chance of sustained profitability, disregarding a potential blockbuster tie up with Kellogs, Coca Cola etc. Thanks
Perhaps i should say
optibiotix-ir.com accessible as optibiotix.com still not on firefox
nevermind the important info re shareholding available and other investor info
mol
Sorry martinu
I was away at time
but selling they were
mol
Website now accessible
and i note as of today
Shares In Issue
As at 28 March 2024, the number of shares in issue was 97,943,161.
Significant Shareholders
As at 29 April 2024, significant shareholders that hold more than 3% of the share capital of OptiBiotix Health Plc, and shareholdings of any other directors are detailed below:
Number Ordinary Shares %
Stephen O'Hara (Director) 10,212,986 10.43
Finance Yorkshire Seedcorn Fund (FYSCF) 5,713,314 5.83
Stephen O'Hara holds 6,099,135 shares under Option
Directors' Shareholders
Number Ordinary Shares %
Stephen O'Hara (Director) 10,212,986 10.43
Neil Davidson (Director) 503,000 0.51
Sean Christie (Director) 150,000 0.15
Graham Myers (Director) 125,000 0.13
So FYSF have reduced their holding by 1375000 between 16 Feb and 29 Apr 24
mol
Opti online was never off on firefox but optibiotix.com is still unaccessible even after clearing my cache files
mol
Fyi. optibiotix.online & .com are both up again.
Mol, let's nail the myth that the placing for just £1.3M gross was to keep the lights on, it was to:
"The net proceeds of the Fundraise will be utilised to invest in driving sales growth by:-
1. active account management of existing partners by co-investing in publicity, marketing, and promotions to increase sales;
2. increased presence of the Company's stands at major exhibitions to attract new partners, particularly in the USA and India to mitigate dependency on a small number of partners;
3. investing in marketing the Company's products to grow sales on e-commerce platforms in India, China, USA, Europe, and the Gulf States; and
4. launch its second generation SweetBiotix and MicroBiome Modulator products."
Note with regards point 3, we have subsequently been informed that "The Company intends to promote heavily on TikTok and Tmall in March and April 2024 with new stock and hope to have a clearer picture of likely regular monthly sales going forward after this period. A TikTok channel has been established in the UK with a view to emulating the success obtained with TikTok China. The Company's Amazon Europe sales channel is now active and the Company is working on ways to deliver products through Amazon Prime. The aim is to launch product on Amazon UAE in late Q1 2024 and Amazon India in early Q2 2024." Consequently, as the UK TikTok site has only just been established, give it time eh after all the TikTok site in China resulted in "E-commerce sales for 2023 were 287% up on 2022 driven by strong growth in China of gummies and large increases in Amazon Prime subscriptions. This progress led the consumer health business to profitability in October and November 2023. Gummy supply and sales in China vary between £20,000 to £50,000 per month partially moderated by stock availability and the Chinese New Year"
That said SOH really does not help himself by cherry picking figures and using them out of context. His statement that "In addition to founding and developing three companies, OptioBiotix layered its development portfolio by creating first generation products (principally SlimBiome® and subsequently WellBiome® in prebiotics and LPLDL® in probiotics) of relatively moderate development risk using existing science, whilst in parallel developing more innovative second-generation products (SweetBiotix®, MicroBiome Modulators) that offer the potential for larger future returns. This strategy allowed the Company to achieve combined revenues of £2.2m in 2021 with both the probiotic (now ProBiotix Health plc) and prebiotic trading businesses being EBITDA profitable in both years. " fails to recognise that the figures were artificially inflated because of Covid overstocking that led to the dreadful figures in 2022 where partners ran down their stocks instead of ordering more. If SOH wants to make a go of first gen products he needs to win over big Customers such as kelloggs which should not prove insurmountable given the obesity rates ar
Mol42 - same with Google Chrome just now - optiobiotix.com is STILL down. Anyone know who to notify about this?:
This site can’t be reached
optibiotix.com took too long to respond.
Running Windows Network Diagnostics
ERR_CONNECTION_TIMED_OUT
Not that he will care Mol but it's a real warning sign that someone with your deep knowledge of the company is on the verge of throwing it in.
As opposed to tick tock
https://www.tiktok.com/@optibiotix
i'm no expert re tiktok/instagram/facebook etc
but the numbers following etc the above are pathetic after all this time
and i cannot access the optibiotix website on firefox since my return from holiday
The page you are trying to view cannot be shown because the authenticity of the received data could not be verified.
Please contact the web site owners to inform them of this problem.
nothing on boots either
jees some things never change with opti
as i have previously noted - i'm giving him to end of this year - at the latest - tick tock
mind not that he will give a ........... and nor should he in response to a BB and his latest placing to keep the lights on
nevermind the gloss put on it within the rns
mol
Sure, but that’s a totally different issue from how much pay he’s awarded or awards himself.
To be fair, SOH and family have a lot of skin in OPTI, much more so than SBTX.
Yes Andrew, we had the strategic and commercial update RNS in Feb. To help make sense of the meaningless percentages; THG took 3 metric tonnes in 2022 so the 36.8% higher uptake in 2023 represents sales of £123K. Can't help you with the H&B figures as no sales took place to them in 2022 so "sales up substantially" could mean anything.
Progress against the stated aim for 2023, each B/U (India, US, B2B and e-Commerce) to be profitable by the end 2023 at least on a month by month basis; B2B and e-Commerce achieved profitability, at least for a month or two, the others didn't.
Sweetbiotix - The Company has included SweetBiotix® in a finished product for a large global partner with a view for an upcoming launch. The Company hopes to see SweetBiotix® in an increasing number of products launched throughout 2024. SOH added in response to a question I raised through TW, "We still intend to launch sweetbiotix as a bulk sugar replacement. These two approaches are not mutually exclusive. We have been surprised and somewhat pleased that progress has been made so quickly with a large corporate in terms of inclusion in a final product."
Aspex - totally agree about TW. SOH should never have gone near him. And I'm very surprised he ever did.
Not sure about SOH's paycheque. It certainly looks disproportionate so far, given where we are and how long it's taken us to get there. But Sweetbiotix might yet be a game changer, which would then cast SOH's remuneration in a very different light.
However, you could still argue that UNLESS/UNTIL that happens, more restraint should have been exercised.
Sorry I mean H2 for 2023
Have we had any guidance on H2 revenues this year, or just the usual signing of deals and future prospects speech?
The thing that surprised me the most is that SOH who is a decent type has been so gullible to associate himself with the TW rubbish machine and has not yet divorced himself.
While I accept the Covid affected everything we should be in a much better place by now.
The missing link IMHO was not raising capital when the share price was over a quid. That was a SOH ego trip by not wishing to dilute his capital.
I am offended by the paycheque that SOH has continued to extract well beyond any excuses to justify it.
IMO, TW is a manipulating shyster only in it for his own benefit. IMO, probably playing both sides. To be avoided.
This motivated me to check how long I've actually been invested here. Since April 2015 it seems. That stuns me. Bought in originally at about 35p and saw a quick rise to a pound. Since then it was a long slow decline which saw me average down all the way to the single figures.
If I'd have bought Bitcoin instead Id be a billionaire 😂😂
Oh well, hopefully this is the year. Amazing to think that people have earned a wage out of this for so long without turning a profit on the product.